González-Ojeda Alejandro, Cervantes-Guevara Gabino, Chejfec-Ciociano Jonathan Matías, Cervantes-Cardona Guillermo Alonso, Acevedo-Guzman Daniel, Puebla-Mora Ana Graciela, Cortés-Lares José Antonio, Chávez-Tostado Mariana, Álvarez-Villaseñor Andrea Socorro, Cervantes-Pérez Enrique, Ramos-Álvarez Mónica Patricia, Pacheco-Vallejo Luis Raúl, Barbosa-Camacho Francisco José, Fuentes-Orozco Clotilde
Unidad de Investigación Biomédica 02, Hospital de Especialidades del Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico.
Departamento de Bienestar y Desarrollo Sustentable, Centro Universitario del Norte, Universidad de Guadalajara, Colotlán, Jalisco, Mexico.
Dermatol Ther. 2022 Sep;35(9):e15703. doi: 10.1111/dth.15703. Epub 2022 Jul 26.
Melasma is a common circumscribed hypermelanosis of sun-exposed areas of the skin. Platelet-Rich Plasma therapy has been evidenced to inhibit melanin synthesis in animals and humans. To determine the effectiveness of platelet-rich plasma as a treatment for melasma. Twenty female patient with melasma were involved in this study. The intervention included three Platelet-Rich Plasma application sessions at 15-day intervals. Patients were evaluated before and after treatment. Variables measured included the facial melanin concentration using the melasma area and severity index score, melasma quality of life scale satisfaction grade, and histologic changes. Mean age was 41 ± 7 years. An initial MELASQOL score of 42 ± 14.8 and final score of 16.6 ± 7.2 (p = 0.008) were reported; the initial and final MASI score were 15.5 ± 8.4 and 9.5 ± 7.2 (p = 0.001), respectively. The dermatoscopy examination revealed a decrease in pigmentation after intervention (p = 0.001). Histopathologic improvement was detected in reductions in cutaneous atrophy (14 [70%] vs. 11 [55%]), solar elastosis (15 [75%] vs.11 [55%]), and inflammatory infiltrate (9 [45%] vs. 6 [30%]), before and after treatment, respectively. The intervention was associated with decreased intensity of the melasma patch and improved skin quality, shown by the MELASQOL and MASI scores.
黄褐斑是一种常见的皮肤暴露于阳光下区域的局限性色素沉着过度。富含血小板血浆疗法已被证明在动物和人类中可抑制黑色素合成。为了确定富含血小板血浆治疗黄褐斑的有效性。本研究纳入了20名患有黄褐斑的女性患者。干预措施包括每隔15天进行三次富含血小板血浆应用疗程。在治疗前后对患者进行评估。测量的变量包括使用黄褐斑面积和严重程度指数评分的面部黑色素浓度、黄褐斑生活质量量表满意度等级以及组织学变化。平均年龄为41±7岁。报告的初始黄褐斑生活质量量表（MELASQOL）评分为42±14.8，最终评分为16.6±7.2（p = 0.008）；初始和最终的黄褐斑面积和严重程度指数（MASI）评分分别为15.5±8.4和9.5±7.2（p = 0.001）。皮肤镜检查显示干预后色素沉着减少（p = 0.001）。治疗前后分别检测到组织病理学改善，表现为皮肤萎缩减少（14例[70%]对11例[55%]）、日光性弹力纤维变性减少（15例[75%]对11例[55%]）和炎症浸润减少（9例[45%]对6例[30%]）。如MELASQOL和MASI评分所示，该干预与黄褐斑斑块强度降低和皮肤质量改善相关。
